Anzeige
Meldung des Tages: Revolutionäre Entwicklung im Megatrend – Der KI-Durchbruch für Pflege und Sicherheit!

Avidity Biosciences Aktie News

Aktie
WKN:  A2P5NK ISIN:  US05370A1088 US-Symbol:  RNA Branche:  Biotechnologie Land:  USA
72,93 $
+0,19 $
+0,26%
61,736 € 03.02.26
Depot/Watchlist
Marktkapitalisierung *
7,37 Mrd. €
Streubesitz
-
KGV
-16,07
Index-Zuordnung
-

Avidity Biosciences News

02.02.26 - PR Newswire
Avidity Biosciences Announces Expected Record Date for Spin-Off
Avidity Biosciences Announces Expected Record Date for Spin-Off PR Newswire
30.01.26 - PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TBHC, RNA, NEW, and TWO
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TBHC, RNA, NEW, and TWO PR Newswire
01.12.25 - PR Newswire
Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights PR Newswire
01.12.25 - PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--TCBX, RNA, ATXS, and FSUN
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--TCBX, RNA, ATXS, and FSUN PR Newswire
21.11.25 - PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-WTRG, RNA, FIZN, and TCBX
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-​WTRG, RNA, FIZN, and TCBX PR Newswire
19.11.25 - PR Newswire
Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44
Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44 PR Newswire
10.11.25 - PR Newswire
Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights
Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights PR Newswire
07.11.25 - PR Newswire
Halper Sadeh LLC Encourages WTRG, PLYM, RNA Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages WTRG, PLYM, RNA Shareholders to Contact the Firm to Discuss Their Rights PR Newswire
30.10.25 - PR Newswire
Halper Sadeh LLC Encourages RNA, JAMF, AWK Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages RNA, JAMF, AWK Shareholders to Contact the Firm to Discuss Their Rights PR Newswire
28.10.25 - PR Newswire
Shareholder Alert: The Ademi Firm investigates whether Avidity Biosciences Inc. is obtaining a Fair Price for its Public Shareholders
Shareholder Alert: The Ademi Firm investigates whether Avidity Biosciences Inc. is obtaining a Fair Price for its Public Shareholders PR Newswire
27.10.25 - PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Avidity Biosciences, Inc. (NASDAQ: RNA)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Avidity Biosciences, Inc. (NASDAQ: RNA) PR Newswire
27.10.25 - PR Newswire
HALPER SADEH LLC ENCOURAGES ADVM, PLYM, RNA SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
HALPER SADEH LLC ENCOURAGES ADVM, PLYM, RNA SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS PR Newswire
27.10.25 - wallstreetONLINE Redaktion
Biotech-Perle aus den USA: Novartis greift zu: 12-Milliarden-Dollar-Deal soll Wachstumsschub bringen
Der Schweizer Pharmariese Novartis setzt seine Einkaufstour fort – und wagt mit der Übernahme des US-​Biotechunternehmens Avidity Biosciences einen Milliarden-​Coup. Rund 12 ...
26.10.25 - PR Newswire
Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG
Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG PR Newswire
16.10.25 - PR Newswire
Avidity Biosciences to Participate in Upcoming Investor Conference
Avidity Biosciences to Participate in Upcoming Investor Conference PR Newswire
13.10.25 - PR Newswire
Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026
Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 PR Newswire
06.10.25 - PR Newswire
Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society
Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society PR Newswire
15.09.25 - PR Newswire
Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire
11.09.25 - PR Newswire
Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock
Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock PR Newswire
10.09.25 - PR Newswire
Avidity Biosciences Announces Proposed Public Offering of Common Stock
Avidity Biosciences Announces Proposed Public Offering of Common Stock PR Newswire

Newssuche

Videos

newspaper
03.02.26
2026 02 03 17 34 Trendjumper Einführung
Zunächst inormieren wir unsere Stammkunden bezüglich des bevorstehenden Seminars und bieten für ... Mehr »